Ara-C+VP-16+G-CSF Ara-C+Mitox+G-CSF 4 F/47 yr M4 Ida+Ara-C Ara-C+Ida+G-CSF Ara-C+Mitox+G-CSF 5 M/38 yr M1 Ida+Ara-C Ara-C+Ida+G-CSF Ara-C+Mitox+G-CSF 6 M/44 yr M1 Ida+Ara-C Ara-C+Ida+G-CSF Ara-C+Mitox+G-CSF Ida = idarubicin; BHAC · N4-behenoyl-1-d-arabinosylcytosine; 6-TG = 6-thioguanine; Ara-C = cytosine arabinoside; VP-16 = etoposide; Mitox = mitoxantrone.
cells were collected by CS3000+ during the recovery phase, following respective consolidation chemotherapy. The conditioning regimen was identical to that of Harada et al 1 (ie the G-CSF was administered concurrently with high-dose chemotherapy (busulfan, etoposide and ara-C)). One difference was that we added G-CSF (5 g/kg) starting 7 days after PBSCT until ANC recovery to more than 1000/l. The major regimen-related toxicity was composed of mucositis (grades II-III, median duration 10.0 days) and diarrhea (grades II-III, median duration 9.5 days). There was no death attributable to the regimen-related toxicity.
The details of infused cell doses, time to ANC and platelet recoveries, and clinical outcomes are described in Table  2 . The mean time of ANC recovery to 500/l and 1000/l was 16.5 and 23 days, respectively. The mean time of platelet recovery to 20 000/l and 50 000/l was 34.0 and 113 days, respectively. The platelet recovery time to 50 000/l was markedly prolonged to more than 100 days in four patients (66.7%). Moreover, four patients (66.7%) experienced a relapse of leukemia after transplantation, with a mean interval of 147.5 days after PBSCT. Two patients were in CR status for 31 and 27 months after PBSCT, respectively. Although our preliminary study included a small number of patients, the G-CSF combined marrow ablative chemotherapy and autologous PBSCT resulted in a markedly delayed platelet recovery and no advantages for decreasing the relapse rate of AML.
One possible reason for a delayed platelet recovery might be a low dose of transplanted CD34 + cells. In our study, however, only one patient (case No. 3) had received a low CD34 + cell dose (2.2 × 10 6 /kg). The other three patients with a platelet recovery delayed by more than 100 days seemed to receive a sufficient CD34 + cell dose (Ͼ5 × /kg). Tjan-Heijnen et al 3 demonstrated the impact of G-CSF priming on peripheral blood cell counts during chemotherapy. They showed a significant delay in neutrophil and platelet recovery in the group of small cell lung cancer patients undergoing conventional non-myeloablative chemotherapy with G-CSF primed chemotherapy. However, the implications for giving the G-CSF combined marrow ablative chemotherapy and PBSCT need to be elucidated.
Regarding the relatively high relapse rate of leukemia in our study, we found that the patients in continuous CR were transplanted with a lower number of CD34 + cells (2.2 and 5.7 × 10 6 /kg) than those patients who relapsed (8.8-20.1 × 10 6 /kg). This might suggest the possibility of a higher chance of leukemic cell contamination with an increased dose of transplanted cells. Recently, Pecora 4 pointed out that multiple aphereses were needed in most patients to achieve stem cell doses greater than 5 × 10 6 /kg, and these procedures increased the malignant cell contamination of the apheresis product. In our study, all of the patients who did not suffer a relapse experienced apheresis procedures four times, and the patients with relapse experienced apheresis procedures five to six times. However, this hypothesis requires a parallel study on minimal residual disease to draw any conclusions about the necessity for purging. Another possible measure to decrease the potential for relapse after transplantation is to incorporate one or two cycles of consolidation following the induction therapy before mobilizing and harvesting the hematopoietic stem cells.
Because of the disappointing preliminary results, we are to emphasize their comment in the abstract and conclusions that 'randomized clinical trials must be performed earlier in the course of cGVHD to establish the efficacy of these new drugs'. Although phase II trials suggest drug efficacy, only phase III trials can prove the impact of therapies. This was exactly the case for azathioprine, which was 'promising' in early studies, but which worsened outcome when added to prednisone therapy in a randomized phase III trial.
